DK0814778T3 - Polypeptidholdige farmaceutiske administrationsformer i form af mikropartikler og fremgangsmåde til fremstilling deraf - Google Patents

Polypeptidholdige farmaceutiske administrationsformer i form af mikropartikler og fremgangsmåde til fremstilling deraf

Info

Publication number
DK0814778T3
DK0814778T3 DK96906751T DK96906751T DK0814778T3 DK 0814778 T3 DK0814778 T3 DK 0814778T3 DK 96906751 T DK96906751 T DK 96906751T DK 96906751 T DK96906751 T DK 96906751T DK 0814778 T3 DK0814778 T3 DK 0814778T3
Authority
DK
Denmark
Prior art keywords
polypeptide
microparticles
additives
block
preparation
Prior art date
Application number
DK96906751T
Other languages
English (en)
Inventor
Gerhard Winter
Hans Koll
Thomas Kissel
Michael Morlock
Original Assignee
Roche Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19513659A external-priority patent/DE19513659A1/de
Priority claimed from DE1995142837 external-priority patent/DE19542837A1/de
Application filed by Roche Diagnostics Gmbh filed Critical Roche Diagnostics Gmbh
Application granted granted Critical
Publication of DK0814778T3 publication Critical patent/DK0814778T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK96906751T 1995-03-10 1996-03-07 Polypeptidholdige farmaceutiske administrationsformer i form af mikropartikler og fremgangsmåde til fremstilling deraf DK0814778T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19508612 1995-03-10
DE19513659A DE19513659A1 (de) 1995-03-10 1995-04-11 Polypeptid-enthaltende pharmazeutische Darreichungsformen in Form von Mikropartikeln und Verfahren zu deren Herstellung
DE1995142837 DE19542837A1 (de) 1995-11-17 1995-11-17 Polypeptid-enthaltende pharmazeutische Darreichungsformen in Form von Mikropartikeln und Verfahren zu deren Herstellung
PCT/EP1996/000980 WO1996028143A1 (de) 1995-03-10 1996-03-07 Polypeptid-enthaltende pharmazeutische darreichungsformen in form von mikropartikeln und verfahren zu deren herstellung

Publications (1)

Publication Number Publication Date
DK0814778T3 true DK0814778T3 (da) 2001-09-17

Family

ID=27214925

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96906751T DK0814778T3 (da) 1995-03-10 1996-03-07 Polypeptidholdige farmaceutiske administrationsformer i form af mikropartikler og fremgangsmåde til fremstilling deraf

Country Status (11)

Country Link
US (1) US6346274B1 (da)
EP (1) EP0814778B1 (da)
JP (1) JP4979843B2 (da)
AT (1) ATE201983T1 (da)
AU (1) AU5004196A (da)
CA (1) CA2214889C (da)
DK (1) DK0814778T3 (da)
ES (1) ES2159726T3 (da)
GR (1) GR3036525T3 (da)
PT (1) PT814778E (da)
WO (1) WO1996028143A1 (da)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59607089D1 (de) * 1995-03-10 2001-07-19 Roche Diagnostics Gmbh Polypeptid-enthaltende pharmazeutische darreichungsformen in form von mikropartikeln und verfahren zu deren herstellung
TW518219B (en) 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
KR100274842B1 (ko) * 1998-10-01 2001-03-02 김효근 미립구를 이용한 레티노익산의 서방형 약물방출 시스템
US6465425B1 (en) * 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
DE10024451A1 (de) * 2000-05-18 2001-11-29 Asta Medica Ag Pharmazeutische Darreichungsform für Peptide, Verfahren zu deren Herstellung und Verwendung
WO2001089477A2 (en) * 2000-05-19 2001-11-29 Battelle Memorial Institute Controlled release of materials from polymer matrices
FR2809309B1 (fr) * 2000-05-23 2004-06-11 Mainelab Microspheres a liberation prolongee pour administration injectable
KR100376083B1 (ko) * 2000-07-01 2003-03-15 주식회사 태평양 친수성 또는 염의 형태로 된 약물을 함유하는 서방형생체삽입용 생분해성 고분자 매트릭스
FR2811227A1 (fr) * 2000-07-07 2002-01-11 Philippe Maincent Vecteurs particulaires destines a ameliorer l'absorption orale de principes actifs
US8257744B2 (en) 2000-07-07 2012-09-04 Laboratorios Farmacéuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
US6967028B2 (en) 2000-07-31 2005-11-22 Mainelab Prolonged release microspheres for injectable administration
WO2002094324A1 (en) * 2001-05-18 2002-11-28 Institute Of Materials Research & Engineering Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
JP4510384B2 (ja) * 2001-05-23 2010-07-21 田辺三菱製薬株式会社 骨折治癒促進用組成物
JP4510383B2 (ja) 2001-05-23 2010-07-21 田辺三菱製薬株式会社 軟骨疾患修復治療用組成物
AU2002343681B2 (en) 2001-11-12 2006-07-06 Alkermes Controlled Therapeutics, Inc. Biocompatible polymer blends and uses thereof
KR100449893B1 (ko) * 2001-12-10 2004-09-22 한국과학기술원 폴리에틸렌글리콜을 포함하는 생분해성 고분자를 이용한제자리 임플란트 조성물
DE10206517A1 (de) * 2002-02-16 2003-09-04 Stoess & Co Gelatine Depotarzneimittel, Trägermaterialien für Depotarzneimittel und Verfahren zu deren Herstellung
US6884432B2 (en) * 2002-04-25 2005-04-26 Mayo Foundation For Medical Education And Research Blend, cross-linkable poly(propylene fumarate) for immobilization and controlled drug delivery
CA2490351C (en) * 2002-06-25 2011-11-01 Takeda Pharmaceutical Company Limited Process for producing sustained-release composition
KR101101261B1 (ko) * 2002-07-19 2012-01-04 인스티튜트 오브 머티어리얼스 리서치 & 엔지니어링 생체분해성 삼블럭 공중합체, 이의 합성 방법, 및이로부터 제조된 하이드로겔 및 생체물질
US20040023322A1 (en) * 2002-08-01 2004-02-05 Goodheart Clyde R. Method of producing non-recombinant BMP-2 and use thereof
WO2004039425A1 (ja) * 2002-10-29 2004-05-13 Toray Industries, Inc. 血管塞栓材料
ES2347239T3 (es) * 2002-12-02 2010-10-27 Amgen Fremont Inc. Anticuerpos dirigidos al factor de necrosis tumoral y usos de los mismos.
ATE492292T2 (de) * 2003-04-02 2011-01-15 Ares Trading Sa Flüssige oder gefriergetrocknete pharmazeutische zusammensetzung enthaltend fsh und/oder lh, das nichtionische tensid poloxamer 188 und ein antibakterielles mittel
US8008255B2 (en) * 2003-05-30 2011-08-30 Amylin Pharmaceuticals, Inc. Methods and compositions for enhanced transmucosal delivery of peptides and proteins
ATE414106T1 (de) 2003-06-30 2008-11-15 Domantis Ltd Pegylierte single-domain-antikörper (dab)
ES2232287B1 (es) * 2003-07-04 2006-11-01 Advanced In Vitro Cell Technologies, S.L. Nanoparticulas de derivados polioxietilenados.
DK1660039T3 (da) * 2003-07-18 2017-01-16 Oakwood Laboratories L L C Forebyggelse af reduktion af polymerens molekylvægt, dannelse af urenheder og gelering i polymersammensætninger
ES2527286T3 (es) * 2004-04-30 2015-01-22 Abraxis Bioscience, Llc Microesferas de liberación sostenida y métodos de fabricación y uso de las mismas
US20090069226A1 (en) * 2004-05-28 2009-03-12 Amylin Pharmaceuticals, Inc. Transmucosal delivery of peptides and proteins
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
PL2115029T3 (pl) 2007-02-15 2016-01-29 Tolmar Therapeutics Inc Poli(laktyd/glikolid) o niskim efekcie nagłego uwalniania i sposoby wytwarzania polimerów
US8802156B2 (en) 2007-11-14 2014-08-12 Laboratorios Farmacéuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
EP2074988B1 (en) 2007-12-28 2018-03-14 Industrial Technology Research Institute Sustained release composition and manufacturing method thereof
US9161943B2 (en) 2007-12-31 2015-10-20 Industrial Technology Research Institute Sustained release composition and manufacturing method thereof
WO2010005726A2 (en) * 2008-06-16 2010-01-14 Bind Biosciences Inc. Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same
EA020753B1 (ru) 2008-06-16 2015-01-30 Бинд Терапьютикс, Инк. Терапевтические полимерные наночастицы, содержащие алкалоиды vinca, и их применение
JP6363320B2 (ja) 2008-06-16 2018-07-25 ファイザー・インク 薬剤を装填したポリマーナノ粒子及びその製造方法と使用方法
NZ590343A (en) 2008-07-18 2012-10-26 Bristol Myers Squibb Co Compositions monovalent for cd28 binding and methods of use
US8563041B2 (en) 2008-12-12 2013-10-22 Bind Therapeutics, Inc. Therapeutic particles suitable for parenteral administration and methods of making and using same
WO2010075072A2 (en) * 2008-12-15 2010-07-01 Bind Biosciences Long circulating nanoparticles for sustained release of therapeutic agents
CA2753641C (en) * 2009-02-25 2014-09-16 Supratek Pharma, Inc. Bendamustine cyclopolysaccharide compositions
TR201906255T4 (tr) 2009-12-11 2019-05-21 Pfizer Terapötik partiküllerin liyofilize edilmesine yönelik stabil formülasyonlar.
EP2515942B1 (en) 2009-12-15 2020-02-12 Pfizer Inc. Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
EP2515946B1 (en) 2009-12-23 2019-05-22 The Board of Trustees of the University of Illionis Nanoconjugates and nanoconjugate formulations
GB201009037D0 (en) 2010-05-28 2010-07-14 Univ Surrey Compositions and methods for treating disorders associated with atherosclerotic plaques
KR101913874B1 (ko) 2010-11-10 2018-10-31 인리젠 장기 확대를 위한 주사가능 제제
TWI641396B (zh) 2011-09-23 2018-11-21 Bvw控股公司 醫療共聚物
AU2013315118B2 (en) 2012-09-17 2017-10-05 Pfizer Inc. Process for preparing therapeutic nanoparticles
WO2014066699A1 (en) 2012-10-24 2014-05-01 Tengion, Inc. Renal cell populations and uses thereof
WO2014120916A1 (en) 2013-02-01 2014-08-07 Bristol-Myers Squibb Company Pegylated domain antibodies monovalent for cd28 binding and methods of use
US20140274873A1 (en) * 2013-03-14 2014-09-18 Allergan, Inc. Composition of a sustained-release delivery and method of stabilizing proteins during fabrication process
EP3116547B1 (en) 2014-03-14 2019-06-05 Pfizer Inc Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
JP6519659B2 (ja) * 2015-09-16 2019-05-29 株式会社島津製作所 ナノ粒子の製造方法
US11345914B2 (en) * 2017-07-11 2022-05-31 Tokyo University Of Pharmacy And Life Sciences Composition for delivering nucleic acid and nucleic acid-containing composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5690954A (en) * 1987-05-22 1997-11-25 Danbiosyst Uk Limited Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material
US5554388A (en) * 1989-02-25 1996-09-10 Danbiosyst Uk Limited Systemic drug delivery compositions comprising a polycationi substance
EP0668073B1 (en) * 1994-02-21 1999-04-14 Takeda Chemical Industries, Ltd. Polyester matrix for a pharmaceutical sustained-release preparation

Also Published As

Publication number Publication date
GR3036525T3 (en) 2001-12-31
PT814778E (pt) 2001-11-30
AU5004196A (en) 1996-10-02
EP0814778A1 (de) 1998-01-07
US6346274B1 (en) 2002-02-12
JPH11501642A (ja) 1999-02-09
CA2214889C (en) 2005-05-24
ES2159726T3 (es) 2001-10-16
JP4979843B2 (ja) 2012-07-18
WO1996028143A1 (de) 1996-09-19
EP0814778B1 (de) 2001-06-13
CA2214889A1 (en) 1996-09-19
ATE201983T1 (de) 2001-06-15

Similar Documents

Publication Publication Date Title
DK0814778T3 (da) Polypeptidholdige farmaceutiske administrationsformer i form af mikropartikler og fremgangsmåde til fremstilling deraf
DK0785776T3 (da) Fremstilling af proteinmikrosfærer, film og coatings
BR9915198A (pt) Composto dds e método para medição do mesmo
DK1137400T3 (da) Præparater indeholdende et peptid og polymælkesyre-glycolsyre egnet til fremstilling af subkutane implantater med en forlænget frigivelsesperiode
DE69637480D1 (de) Bioaktive il-12 fusionsproteine
ATE335011T1 (de) Verfahren zur vernetzung von hyaluronsäure mit polymeren
ATE344275T1 (de) Verfahren zur herstellung eines agglomerats von n-(n-(3,3-dimethylbutyl)-l- alpha aspartyl)-l- phenylalanine-1-methylester
ATE350015T1 (de) Mikropartikelzusammensetzungen und verfahren zu ihrer herstellung
CY1106620T1 (el) Μεθοδος για την παραγωγη τριπεπτιδιων
DK0513072T3 (da) Forbedret cyclodextrinbaseret erythropoietinformulering
DE68927669D1 (de) Verfahren zur herstellung von in lösungsmitteln verdünnbaren mikroträgern
ATE252375T1 (de) Bioabbaubare mikropartikeln mit verzögerter wirkstofffreisetzung
IT8920169A0 (it) Derivati di acidi biliari, loro preparazione e composizioni farmaceutiche che li contengono.
HUP0302050A2 (hu) Peptidek beadására alkalmas gyógyszerforma, eljárás az elżállítására és alkalmazása
ATE127846T1 (de) Herstellung von hv/hb copolymer.
DE69900756T2 (de) Verwendung von hmg proteinen zur herstellung von arzneimitteln mit zytotoxischer wirkung
DK1014948T3 (da) Lyofiliseret farmaceutisk præparat som er beregnet til at efterligne et lægemiddel på basis af proteiner eller polypeptider
Li et al. Engineering hydrolytic degradation behavior of poly (lactic-co-glycolic acid) through precise control of monomer sequence
ES2153648T3 (es) Polimeros con estado fisico y bioerosionabilidad controlados.
DK1165052T3 (da) Mikroporöst, ekspanderet, isotropt eller struktur med hurtig oplösning til farmaceutisk, veterinær, diætetisk, levnedsmiddelmæssig eller kosmetisk anvendelse og fremgangsmåde til opnåelse deraf
JPH01160496A (ja) 融合タンパク質の選択的分解方法
DE69713477T2 (de) Verfahren zur Herstellung von Polyhydroxycarbonsäure
Belikov et al. Plasteins. Their preparation, properties, and use in nutrition
NO980103L (no) Stabilisert farmasöytisk preparat som omfatter et veksthormon og et peptid omfattende minst én basisk aminosyrerest og minst én sur aminosyrerest
DE60108889D1 (de) Verfahren zur herstellung von 5-hydroxymethyl-2-oxazolidinon und neues zwischenprodukt